NASDAQ : YARW
Yarrow Bioscience, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 20 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 186.09M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 166.83M |
| Enterprise Value | 66.83M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 9.30M |
| Shares Outstanding | 9.30M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -28.29% |
| Owned by Insiders (%) | 0.90% |
| Owned by Institutions (%) | 32.98% |
| Float | 8.63M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.78 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 297.91 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.40 |
| Quick Ratio | 1.40 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -13.78% |
| Weighted Average Cost of Capital (WACC) | 15.69% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$40.57M |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.08 |
| 52-Week Price Change | +0.82% |
| 50-Day Moving Average | 25.21 |
| 200-Day Moving Average | 30.72 |
| Relative Strength Index (RSI) | 34.10 |
| Average Volume (20 Days) | 164,477 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 131,992 |
| Short Previous Month | 189,586 |
| Short % of Shares Out | 1.42% |
| Short % of Float | 1.53% |
| Short Ratio (days to cover) | 1.02 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -3.98M |
| Pretax Income | -283.98M |
| Net Income | -283.98M |
| EBITDA | n/a |
| EBIT | -3.98M |
| Earnings Per Share (EPS) | -$66.82 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 99.99M |
| Total Debt | n/a |
| Net Cash | 99.99M |
| Net Cash Per Share | $10.75 |
| Equity (Book Value) | 28.86M |
| Book Value Per Share | -16.70 |
| Working Capital | 28.45M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 560,000 |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -16.93M |
| FCF Per Share | -$1.82 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -372.66% |
| FCF Yield | -10.15% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $57.00 |
| Price Target Difference | 217.90% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jul 27, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:50 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |